<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39424114</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0442</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Travel medicine and infectious disease</Title><ISOAbbreviation>Travel Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-migration infection with SARS-CoV-2 in Venezuelan migrants: A laboratory-based epidemiological observational study.</ArticleTitle><Pagination><StartPage>102772</StartPage><MedlinePgn>102772</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tmaid.2024.102772</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1477-8939(24)00089-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since 2015, over 6 million Venezuelans migrated to Colombia and neighboring countries. While most people adhered to lockdown measures, migrants kept moving during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">To investigate the extent of migration-associated SARS-CoV-2 infections, we interviewed 1209 adult Venezuelan migrants upon arrival to Bucaramanga, Colombia, 200 km from the Colombian-Venezuelan border along the main migration route during April-September 2021, collected individual-level socio-economic and clinical data, sampled blood and saliva, and assessed SARS-CoV-2 infection by serological, molecular and phylogenetic tools.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SARS-CoV-2 RT-PCR positivity was 1.9 % (95 % Confidence Interval (CI), 1.2-2.9) without varying significantly over the study period (chi-square, p = 0.922) and significantly associated with stay in Colombia &gt;14 days (p = 0.018; prevalence ratio 3.3, 95 % CI, 1.2-8.7). Pre-existing SARS-CoV-2-specific antibodies were neither significantly associated with preventing infection (Chi-square, p = 0.188), nor symptom development (Fisher, p = 0.246). Predominance and time of detection of SARS-CoV-2 Mu and Gamma variants in migrants in comparison to available genomic data suggested infection predominantly in Colombia. SARS-CoV-2 IgG-based seroprevalence was 34.2 % (95 % CI, 31.5-36.9). Detection of SARS-CoV-2-specific antibodies was significantly associated with previous contact with infected individuals (p = 0.002).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SARS-CoV-2 infection occurred predominantly after immigration, potentially facilitated by densely populated border camps. Improved infrastructure and health care will prevent migration-associated spread of COVID-19 and other infectious diseases.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Oliveira-Filho</LastName><ForeName>Edmilson F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Vega</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Universidad de Santander, Escuela de Medicina, Facultad de Ciencias Médicas y de la Salud Bucaramanga, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreira-Soto</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuchel</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freyle-Román</LastName><ForeName>Ivette K</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Universidad Industrial de Santander, Medicine School, Bucaramanga, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora-Guevara</LastName><ForeName>Eliana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universidad Industrial de Santander, Medicine School, Bucaramanga, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rincón-Orozco</LastName><ForeName>Bladimiro</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Universidad Industrial de Santander, Medicine School, Bucaramanga, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drexler</LastName><ForeName>Jan Felix</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany; German Centre for Infection Research (DZIF), associated partner site Charité, Berlin, Germany. Electronic address: felix.drexler@charite.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Travel Med Infect Dis</MedlineTA><NlmUniqueID>101230758</NlmUniqueID><ISSNLinking>1477-8939</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Migrants</Keyword><Keyword MajorTopicYN="N">Racism</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Seroprevalence</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39424114</ArticleId><ArticleId IdType="doi">10.1016/j.tmaid.2024.102772</ArticleId><ArticleId IdType="pii">S1477-8939(24)00089-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>